Checkpoint Therapeutics Inc - Company Profile
Powered by
All the data and insights you need on Checkpoint Therapeutics Inc in one report.
- Save hours of research time and resources with
our up-to-date Checkpoint Therapeutics Inc Strategy Report
- Understand Checkpoint Therapeutics Inc position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Checkpoint Therapeutics Inc (Checkpoint Therapeutics), a subsidiary of Fortress Biotech Inc, is a clinical-stage biopharmaceutical company that acquires, develops, and commercializes novel treatments for solid tumor cancers. Its lead product candidate, CK-101 molecule is in Phase I clinical trials for the treatment of patients with positive epidermal growth factor receptor (EGFR). The company’s other lead product candidate CK-301, is an anti-PD L1 antibody intended for the treatment of patients with non-small cell lung cancer (NSCLC) and other solid tumors. Checkpoint Therapeutics’ other pipeline products include a portfolio of human immuno-oncology agents and targeted anti-cancer agents intended for the treatment of multiple types of cancer including renal cell carcinoma, EGFR mutation-positive NSCLC and multiple forms of cancer. The company also works in partnership with other pharmaceutical companies to co-develop its antibodies. Checkpoint Therapeutics is headquartered in New York, the US.
Checkpoint Therapeutics Inc premium industry data and analytics
Products and Services
Products |
---|
Pipeline |
CK-301 anti- PDL1- for Lung Cancer and other tumors |
CK-101 EGFR Inhibitor Program –for NSCLC |
XYZ |
XYZ |
XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
Year | Event | Description |
---|---|---|
2023 | Regulatory Approval | In January, the company submitted Biologics License application to the FDA. |
2023 | Regulatory Approval | In March, the FDA accepted the company’s Biologics License Application. |
2022 | Others | In May, the company received Pediatric Investigation Plan Waivers from European Medicines Agency and U.K. Medicines & Healthcare Products Regulatory Agency. |
Competitor Comparison
Key Parameters | Checkpoint Therapeutics Inc | Merck & Co Inc | Bristol-Myers Squibb Co | Gilead Sciences Inc | Telix Pharmaceuticals Ltd |
---|---|---|---|---|---|
Headquarters | United States of America | United States of America | United States of America | United States of America | Australia |
City | Waltham | Kenilworth | Princeton | Foster City | Melbourne |
State/Province | Massachusetts | New Jersey | New Jersey | California | Victoria |
No. of Employees | 23 | 72,000 | 34,100 | 18,000 | 234 |
Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
Name | Position | Board | Since | Age |
---|---|---|---|---|
Michael S. Weiss | Chairman | Executive Board | 2015 | 57 |
James F. Oliviero | Director; Chief Executive Officer; President | Executive Board | 2015 | 47 |
Garrett Gray | Chief Financial Officer | Senior Management | 2020 | 35 |
Neil Herskowitz | Director | Non Executive Board | 2015 | 66 |
Lindsay A. Rosenwald, M.D. | Director | Non Executive Board | 2014 | 68 |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Access more premium companies when you subscribe to Explorer